SEATTLE (Reuters) - A drug-resistant superbug infected 32 people at a Seattle hospital over a two-year period, with the bacteria spreading through contaminated medical scopes that had been cleaned to the manufacturer's recommendation, officials said on Thursday.
and they are not alone.
About two-thirds are from a mutated form of the H3N2 virus, reducing the efficacy of the flu vaccine designed to target an earlier form of the virus.
This does not appear to be Inovio. It appears that the race is on!
"Our results suggest that luring HIV out of hiding is winning only half the battle," says senior investigator Robert Siliciano, M.D., Ph.D., professor of medicine, molecular biology and genetics at the Johns Hopkins University School of Medicine. "We found that these pools of dormant virus carry mutations that render HIV invisible to the very immune cells capable of disarming it, so even when the virus comes out of hiding, it continues to evade immune detection."
Using a technique known as deep sequencing to reveal HIV's genetic features down to a single infected cell, scientists analyzed blood samples from 25 HIV-infected patients, 10 of whom had started therapy early—within three months of infection—while the rest had begun treatment after the three-month mark, when HIV infection enters its chronic stage
JAN 12-14, 2015
San Francisco, CA
We're creating the vaccines of tomorrow. We are We're creating the vaccines of tomorrow. We are revolutionizing vaccines.
Did you get that part "HIV"?
Who ya gonna call?
Thought to be transmitted by ticks, the virus "was fast-moving and severe, causing lung and kidney failure, and shock," The New York Times reported, killing the previously healthy man after only 10 days in the hospital.
This time it’s not Ebola but a mosquito-borne disease called chikungunya, which causes debilitating joint pain and has infected more than 1 million people just this year. Originating in Africa, the virus has rapidly spread into the Caribbean and Central and South Americas, with a smattering of cases in the United States. Chikungunya is nothing like Ebola, but scientists who study it find themselves in a predicament similar to Ebola researchers: Despite decades of study, there’s still no way to treat or prevent it, due in part to a lack of interest from drug companies.
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has entered a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, and OncoSec’s ImmunoPulse (intratumoral IL-12) in metastatic melanoma
The drug was approved in the U.S. at a dose of 2 mg/kg every three weeks for the treatment of patients suffering from unresectable or metastatic melanoma and whose disease progressed after treatment with Bristol-Myers Squibb Company’s (BMY) Yervoy and a BRAF inhibitor, if the BRAF V600 mutation was positive. According to the company, 900 of the 1,200 patients who may be eligible for Keytruda are already on the treatment.
Last week Merck announced encouraging early results from the ongoing phase Ib KEYNOTE-013 study on Keytruda
It's obviously from the company website. It's from 10/2014. It's huge!
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.2 billion in 2013, has about 7,600 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index
Dr. J. Joseph Kim, Inovio's President and CEO, said, "More effective antiviral drugs have changed the prognosis for patients with hepatitis C; however, treatment failures remain and combination with an immunotherapeutic approach could make the difference for many patients. In preclinical studies, Inovio's HCV immunotherapy has shown to generate powerful T cell responses in the liver, which could be important in clearing HCV-infected liver cells. We have already shown in published clinical studies that our vaccines generate best-in-class T-cell responses. In this study, the effects of Inovio's HCV immunotherapy will be directly tested in patients who have previously failed standard drug therapies.